ISSN:

జర్నల్ ఆఫ్ ఎకాలజీ అండ్ టాక్సికాలజీ

అందరికి ప్రవేశం

మా గ్రూప్ ప్రతి సంవత్సరం USA, యూరప్ & ఆసియా అంతటా 3000+ గ్లోబల్ కాన్ఫరెన్స్ ఈవెంట్‌లను నిర్వహిస్తుంది మరియు 1000 కంటే ఎక్కువ సైంటిఫిక్ సొసైటీల మద్దతుతో 700+ ఓపెన్ యాక్సెస్ జర్నల్‌లను ప్రచురిస్తుంది , ఇందులో 50000 మంది ప్రముఖ వ్యక్తులు, ప్రఖ్యాత శాస్త్రవేత్తలు ఎడిటోరియల్ బోర్డ్ సభ్యులుగా ఉన్నారు.

ఎక్కువ మంది పాఠకులు మరియు అనులేఖనాలను పొందే ఓపెన్ యాక్సెస్ జర్నల్స్

700 జర్నల్స్ మరియు 15,000,000 రీడర్లు ప్రతి జర్నల్ 25,000+ రీడర్లను పొందుతున్నారు

ఇండెక్స్ చేయబడింది
  • గూగుల్ స్కాలర్
ఈ పేజీని భాగస్వామ్యం చేయండి

నైరూప్య

Patients' Reimbursement Trade-offs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments are Simulated by Mushroom Cementation of Bio - based products from Microbial degradation of Radioactive Cellulosic-Based Material

Jacky P

In the current study, solidification of bioproducts produced by the bioremediation of a combination of radioactive waste made of solid cellulose was investigated in Portland cement. After 28 and 90 days of cure, the resultant solidified waste form was evaluated for mechanical integrity. Over the course of 540 days, the chemical performance of the cement-waste form was also assessed in various leaching media. The collected provided useful information regarding the final cement-waste form that contained the radioactive bioproducts in terms of its mechanical, physical, and chemical capabilities. Additionally, it revealed that cement can operate as a first line of defence against the release of radioactive pollutants from radioactive wastes to the environment and can offer a highly durable form that ensures the long-term stability of the solidified waste material.

The purpose of this study was to evaluate patients' preferences for when to begin systemic therapy and how to help them decide whether to trade off certain severe adverse events (AEs) for additional progression-free survival months (PFS). Materials and Techniques A direct-elicitation question and a discrete-choice experiment (DCE) were completed online by adults in France, Germany, and Spain who have been diagnosed with DTC and have received at least one RAI therapy. Respondents were asked if they would choose not to get treatment if their tumour was RAI-R in a direct-elicitation question. Respondents had 12 pairs of fictitious RAI-R DTC treatment profiles to select from in the DCE. Dimensions of effectiveness (PFS) and safety served as the benchmarks for profiling (severe hand-foot skin reaction [HFSR], severe proteinuria, and severe hypertension). The estimated logit model used main-effects randomparameters.The survey had 134 patients respond. Eighty-six percent of patients chose therapy over a "wait and see" strategy. Compared to the risks of proteinuria and HFSR, patients gave more weight to the risk of severe hypertension.In contrast to watchful waiting, DTC patients preferred therapy for RAI-R DTC. Severe proteinuria or HFSR seems to have less of an impact on patients' decisions than their worries about the possibility of developing severe hypertension.